key: cord-0857454-3taykdr1
authors: Weitzel, Thomas; Legarraga, Paulette; Iruretagoyena, Mirentxu; Pizarro, Gabriel; Vollrath, Valeska; Araos, Rafael; Munita, José M.; Porte, Lorena
title: Head-to-head comparison of four antigen-based rapid detection tests for the diagnosis of SARS-CoV-2 in respiratory samples
date: 2020-05-27
journal: bioRxiv
DOI: 10.1101/2020.05.27.119255
sha: 9bc12a21289fca436bb7507e0cda102dab079e21
doc_id: 857454
cord_uid: 3taykdr1

In the context of the Covid-19 pandemic, the development and validation of rapid and easy-to-perform diagnostic methods are of high priority. We compared the performance of four rapid antigen detection tests for SARS-CoV-2 in respiratory samples. Immunochromatographic SARS-CoV-2 assays from RapiGEN, Liming bio, Savant, and Bioeasy were evaluated using universal transport medium containing naso-oropharyngeal swabs from suspected Covid-19 cases. The diagnostic accuracy was determined in comparison to SARS-CoV-2 RT-PCR. A total of 111 samples were included; 80 were RT-PCR positive. Median patients’ age was 40 years, 55% were female, and 88% presented within the first week after symptom onset. The evaluation of the Liming bio assay was discontinued due to insufficient performance. The overall sensitivity values of RapiGEN, Liming bio, and Bioeasy tests were 62.0% (CI95% 51.0–71.9), 16.7% (CI95% 10.0–26.5), and 85.0% (CI95% 75.6–91.2), respectively, with specificities of 100%. Sensitivity was significantly higher in samples with high viral loads (RapiGEN, 84.9%; Bioeasy, 100%). The study highlighted the significant heterogeneity of test performance among evaluated assays, which might have been influenced by the use of a non-validated sample material. The high sensitivity of some tests demonstrated that rapid antigen detection has the potential to serve as an alternative diagnostic method, especially in patients presenting with high viral loads in early phases of infection. This is particularly important in situations with limited access to RT-PCR or prolonged turnaround time. Further comparative evaluations are necessary to select products with high performance among the growing market of diagnostic tests for SARS-CoV-2.

Since its emergence in 2019, the SARS-CoV-2 pandemic has caused tremendous public 46 health challenges worldwide (1) . Early detection of cases is essential to help curtail this 47

Seventeen of the positive specimens had been used in a previous evaluation of the Bioeasy RDT 112 by our group (15). Assays were tested in parallel from the same sample and by the same trained 113 technician, who was blinded to the RT-PCR results. All test procedures, except the reading of the 114 cassette, were performed under a BSL2 cabinet. Assays with visual output were read by two 115 independent observers, who conferred with a third observer in case of disagreement. Results of 116 the RDTs were compared to those of RT-PCR as reference method; for samples with discordant 117 result, tests were repeated. Demographic and clinical data were obtained from the mandatory 118

Covid-19 notification forms and analyzed in an anonymized manner. Samples with high viral 119 loads (defined as Ct value <25) were compared to those with low viral load (Ct values >25) (16). 120

Statistical analyses were performed with OpenEpi (version 3.01) and GraphPad Prism ( While all four tests were user-friendly, test performances showed significant differences 139 ( Table 2 ). The evaluation of the Liming bio kit was stopped after 19 samples, due to its poor 140 results with a sensitivity of 0% (0/9), specificity of 90% (9/10), and a Kappa coefficient of -0. 1. 141 Sensitivities of the other three assays ranged from 16.7% for the Savant test to 85% for Bioeasy 142 (Table 2) . Similarly, Bioeasy had the highest accuracy (89.2%) and Kappa coefficient (0.8). All 143 three assays had a specificity of 100% and proved robust; invalid results occurred only with 144 RapiGen (n=2) and Savant (n=2) due to insufficient liquid migration. 145

In addition, we correlated the viral loads of samples with true positive and false negative 146 results. As shown in Figure 1 with high viral loads and low viral loads (Ct >25) ( Figure 2) . Indeed, the two assays identified 151 84.9% and 100% of specimens with high viral load, but only 15.4% and 53.8% of those with low 152 viral load, respectively. In case of the Savant assay, although the difference in sensitivity among 153 samples with high and low viral loads remained, it was far less striking (21.2% vs. 7.7%, 154 respectively) (Figure 2 ). RapiGen and Bioeasy had a concordance of 82%, while agreement 155 between these two tests and Savant was 67% and 50%, respectively. As visualized in Figure 3 The evaluated assays are among the 22 antigen detection tests for SARS-CoV-2 available 172 at the time of writing, of which 14 are commercialized with CE (Conformité Européene) 173 marking (13). However, it is important to note that the CE licencing process is based on self-174 reporting of manufacturers, does not grant high performance, and can be misused (18, 19) . 175

Indeed, the challenge and problems presented by this procedure has recently been addressed by 176 the European Commission in light of the evolving Covid-19 pandemic (12). The emerging 177 marketing and use of novel PCR-independent tests in the absence of robust performance data has 178 been criticized and it has the potential to cause more damage than benefit (20, 21). Independent 179 evaluations of such diagnostic assays are therefore urgently needed, with larger comparative still in its infancy and evaluations are scarce (12). Up to now, we only found four publications 182 available (three peer-reviewed), evaluating two assays (15-17, 24) , while comparative studies are 183 lacking. 184

Sensitivity is the most important performance parameter of SARS-CoV-2 antigen 185 detection (12). However, it is also considered the main limiting factor due to experiences with 186 influenza and RSV lateral flow detection kits (6, 25) . Newer biosensor-based methods to detect 187 SARS-CoV-2 antigen have shown promising results and could offer a highly sensitive alternative 188 for rapid diagnosis in the future (26, 27). 189

Our comparison detected significant performance heterogeneity among the evaluated kits. 190

The Bioeasy assay had the highest sensitivity, which was in accordance with our previous 191 evaluation (15). The here reported sensitivity (85%) was almost identical to the value reported by 192 the manufacturer (85.5%). A study from China (with participation of the manufacturer) found an 193 overall sensitivity of 68%; however, for samples with Ct values ≤30, the sensitivity increased to 194 98% (24) . This excellent identification rate in specimens with high viral loads (Ct <25) was 195 confirmed in this report and our recently published study (15). The RapiGen test also showed an 196 acceptable sensitivity (84.9%) with high viral load samples, but was much less sensitive (15.4%) 197

when the viral burden was low. This test had a visual readout, which might have contributed to 198 lower sensitivity. Another assay with visual bands (Respi-Strip CORIS) was recently evaluated 199 in two European studies. Overall sensitivity ranged from 50% to 57.6%; however, detection rates 

2019 novel coronavirus disease (COVID-19): Paving the 276 road for rapid detection and point-of-care diagnostics

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Laboratory testing for 2019 novel coronavirus 283 (2019-nCoV) in suspected human cases

Respiratory Viruses Branch, Division of Viral Diseases

Real-Time RT-PCR Panel for Detection 2019-Novel Coronavirus. Instructions for Use

Diagnostic testing for severe acute respiratory syndrome-related coronavirus-2: A 293 narrative review

Laboratory testing strategy recommendations for 12

COVID-19 in vitro diagnostic tests and their performance (2020/C 122 I/01)

uri=CELEX:52020XC0415(04)&from=EN

SARS-CoV-2 diagnostic pipeline

European Centre for Disease Prevention and Control (ECDC)

Evaluation of novel antigen-based rapid detection test for the 322 diagnosis of SARS-CoV-2 in respiratory samples

Medical Product Alert N°3/2020: Falsified medical 337 products, including in vitro diagnostics

The role of 340 antibody testing for SARS-CoV-2: Is there one?

Serological approaches for COVID-19: Epidemiologic 342 perspective on surveillance and control

Test performance evaluation of SARS-CoV-2 352 serological assays

Diagnosis of SARS-CoV-2 infection and COVID-19: accuracy of 355 signs and symptoms; molecular, antigen, and antibody tests; and routine laboratory markers 356 (Protocol)

Diagnosis of acute respiratory syndrome coronavirus 2 infection by 359 detection of nucleocapsid protein

Towards effective diagnostic assays for COVID-19: a review

Rapid detection of COVID-19 causative virus (SARS-CoV-2) in 365 human nasopharyngeal swab specimens using field-effect transistor-based biosensor